National Centre for Pharmacoeconomics

National Centre for

NCPE Ireland

Blinatumomab is indicated as  monotherapy for the treatment of adults with Philadelphia chromosome negative CD19 positive B-precursor acute lymphoblastic leukaemia (BCP-ALL)  in first or second complete remission with minimal residual disease greater than or equal to 0.1%.

NCPE Assessment Process Complete
Rapid review commissioned 19/08/2019
Rapid review completed 23/09/2019
Rapid Review outcome A full HTA is not recommended. The NCPE recommends that blinatumomab not be considered for reimbursement at the submitted price.*



* This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.